Ned is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
1970 articles by Ned Pagliarulo
-
AstraZeneca immunotherapy combo extends survival in liver cancer trial
Oct. 15, 2021 -
Merck advantage grows as FDA approves Keytruda for first-line cervical cancer
Oct. 14, 2021 -
Relay's targeted cancer drug could be safer than its competitors. Is it more effective?
Oct. 8, 2021 -
Intergalactic Therapeutics launches with $75M to build a new type of gene therapy
Oct. 7, 2021 -
Takeda halts studies of touted sleep disorder drug over safety concern
Oct. 6, 2021 -
J&J asks FDA to clear booster dose of its coronavirus vaccine
Oct. 5, 2021 -
Gilead wins approval of CAR-T therapy in adult leukemia
Oct. 4, 2021 -
5 FDA approval decisions to watch in the fourth quarter
Oct. 1, 2021 -
GSK, Merck KGaA end cancer drug partnership after study results disappoint
Oct. 1, 2021 -
After long wait, Editas reveals first data for CRISPR gene editing treatment
Sept. 29, 2021 -
Eisai, Biogen to test FDA by asking for approval of second Alzheimer's drug
Sept. 28, 2021 -
Biohaven's pipeline takes a hit as drug for rare neurological disease falls short in trial
Sept. 27, 2021 -
CDC recommends Pfizer booster shots for many, overruling advisers on broad use
Sept. 23, 2021 -
AstraZeneca strikes deal with university spinoff to turn RNA into drugs
Sept. 23, 2021 -
US buying 500M more doses of Pfizer coronavirus vaccine for donation to world
Sept. 22, 2021 -
Novartis pushes further into gene therapy for the eye with deal for Swiss startup
Sept. 21, 2021 -
ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up
Sept. 20, 2021 -
FDA advisers support booster dose of Pfizer vaccine in older or high-risk adults
Sept. 17, 2021 -
Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention
Sept. 17, 2021 -
Amgen to advance KRAS drug combination after improved results in colon cancer
Sept. 16, 2021 -
US stocks up on COVID-19 antibody drugs amid shortage concerns
Sept. 15, 2021 -
Fourth trial volunteer dies in Astellas gene therapy study
Sept. 14, 2021 -
Departing FDA officials, WHO leaders argue against broad rollout of COVID-19 booster shots
Sept. 13, 2021 -
Apellis eye drug succeeds in one key study, but falls short in its twin
Sept. 9, 2021 -
'The sky is not falling.' Cautious optimism follows FDA meeting on gene therapy risks
Sept. 7, 2021